{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:42:52Z","timestamp":1778035372262,"version":"3.51.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Invasive candidiasis (IC) is a significant factor for lung transplant recipient (LTR) mortality, especially in the immediate postoperative phase. Receipt of antifungal prophylaxis has demonstrated lower all-cause mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a single-center, retrospective cohort study of LTRs between August 2017 and August 2020. Included patients were adult LTRs with positive Candida cultures preoperatively (donor or recipient) or within 6 weeks postoperatively. Patients were divided into 2 cohorts\u2014bridged and unbridged. The bridged cohort received micafungin in the postoperative period until therapeutic azole concentrations were achieved or up to 2 weeks, whichever was sooner. The primary outcome was a composite of proven or probable invasive candidiasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 117 patients were included in the study, with 68 in the unbridged cohort and 49 in the bridged cohort. There were more cases of IC in the bridged cohort than in the unbridged cohort (P = .011).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In combination with an azole antifungal, micafungin did not prevent IC in postoperative LTRs with cultures positive for Candida species in this cohort. Larger prospective studies are needed to determine the ideal combination and duration of antifungal prophylaxis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae525","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T03:34:57Z","timestamp":1725939297000},"source":"Crossref","is-referenced-by-count":1,"title":["Bridging Echinocandin With Azole Antifungal Therapy on Prevention of Invasive Candidiasis Post\u2013Lung Transplantation"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7536-3899","authenticated-orcid":false,"given":"Taylor","family":"Pasley","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Houston Methodist Hospital , Houston, Texas ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8067-1493","authenticated-orcid":false,"given":"Christopher","family":"Baladad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Alvarado Hospital Medical Center , San Diego, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"DeSear","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Florida Health Shands Hospital , Gainesville, Florida ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solmaz","family":"Karimi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Ohio State University Wexner Medical Center , Columbus, Ohio ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Rubido","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Houston Methodist Hospital , Houston, Texas ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"El Helou","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease and Global Medicine, Department of Medicine, University of Florida , Gainesville, Florida ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Converse","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cleveland Clinic , Cleveland, Ohio ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"2024092714523924400_ofae525-B1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.healun.2017.07.016","article-title":"The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult lung and heart-lung transplantation report-2017; focus theme: allo-graft ischemic time","volume":"36","author":"Chambers","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"2024092714523924400_ofae525-B2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1055\/s-0041-1729173","article-title":"Fungal infection in lung transplantation","volume":"42","author":"Kennedy","year":"2021","journal-title":"Semin Respir Crit Care Med"},{"key":"2024092714523924400_ofae525-B3","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00134-014-3408-3","article-title":"Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002\u20132010)","volume":"40","author":"Lortholary","year":"2014","journal-title":"Intensive Care Med"},{"key":"2024092714523924400_ofae525-B4","doi-asserted-by":"crossref","first-page":"e13812","DOI":"10.1111\/tid.13812","article-title":"Epidemiology of candidemia in lung transplant recipients and risk factors for candidemia in the early posttransplant period in the absence of universal antifungal prophylaxis","volume":"24","author":"Marinelli","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"2024092714523924400_ofae525-B5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.healun.2016.01.007","article-title":"The 2015 International Society for Heart and Lung Transplantation guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: executive summary","volume":"35","author":"Husain","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"2024092714523924400_ofae525-B6","doi-asserted-by":"crossref","first-page":"e13333","DOI":"10.1111\/tid.13333","article-title":"Antifungal prophylaxis in lung transplant recipients: a systematic review and meta-analysis","volume":"22","author":"Pennington","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"2024092714523924400_ofae525-B7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"2024092714523924400_ofae525-B8","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","volume":"26","author":"G\u00f3mez-L\u00f3pez","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2024092714523924400_ofae525-B9","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024092714523924400_ofae525-B10","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/j.1600-6143.2012.04100.x","article-title":"Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, Infectious Diseases Community of Practice","volume":"12","author":"Singh","year":"2012","journal-title":"Am J Transplant"},{"key":"2024092714523924400_ofae525-B11","doi-asserted-by":"crossref","first-page":"e13623","DOI":"10.1111\/ctr.13623","article-title":"Candida infections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Aslam","year":"2019","journal-title":"Clin Transplant"},{"key":"2024092714523924400_ofae525-B12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/tid.12613","article-title":"The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"18","author":"Andes","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"2024092714523924400_ofae525-B13","doi-asserted-by":"crossref","first-page":"e13448","DOI":"10.1111\/tid.13448","article-title":"Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation","volume":"23","author":"Linder","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"2024092714523924400_ofae525-B14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-6143.2010.03375.x","article-title":"Antifungal prophylaxis in lung transplantation\u2014a world-wide survey","volume":"11","author":"Neoh","year":"2011","journal-title":"Am J Transplant"},{"key":"2024092714523924400_ofae525-B15","doi-asserted-by":"crossref","first-page":"e13630","DOI":"10.1111\/ctr.13630","article-title":"Antifungal prophylaxis in lung transplant: a survey of United States\u2019 transplant centers","volume":"33","author":"Pennington","year":"2019","journal-title":"Clin Transplant"},{"key":"2024092714523924400_ofae525-B16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/cid\/ciz156","article-title":"Invasive fungal infection after lung transplantation: epidemiology in the setting of antifungal prophylaxis","volume":"70","author":"Baker","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024092714523924400_ofae525-B17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00005792-199605000-00004","article-title":"Fungal infections in lung and heart-lung transplant recipients: report of 9 cases and review of the literature","volume":"75","author":"Kanj","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"2024092714523924400_ofae525-B18","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/cid\/cix460","article-title":"Donor-derived transmission of Candida auris during lung transplantation","volume":"65","author":"Azar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024092714523924400_ofae525-B19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1086\/423377","article-title":"A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients","volume":"39","author":"De Wet","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024092714523924400_ofae525-B20","doi-asserted-by":"crossref","first-page":"e13692","DOI":"10.1111\/tid.13692","article-title":"Perioperative anidulafungin combined with triazole prophylaxis for the prevention of early invasive candidiasis in lung transplant recipients","volume":"23","author":"Sartain","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"2024092714523924400_ofae525-B21","doi-asserted-by":"crossref","first-page":"e036452","DOI":"10.1136\/bmjopen-2019-036452","article-title":"Risk of invasive candidiasis with prolonged duration of ICU stay: a systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2020","journal-title":"BMJ Open"},{"key":"2024092714523924400_ofae525-B22","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/cid\/civ791","article-title":"Echinocandin resistance in Candida","volume":"61","author":"Perlin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024092714523924400_ofae525-B23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijid.2017.08.017","article-title":"Candida auris: an emerging multidrug-resistant pathogen","volume":"63","author":"Sears","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2024092714523924400_ofae525-B24","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997\u20132016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024092714523924400_ofae525-B25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/QCO.0000000000000111","article-title":"Echinocandin resistance: an emerging clinical problem?","volume":"27","author":"Arendrup","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"2024092714523924400_ofae525-B26","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2024092714523924400_ofae525-B27","doi-asserted-by":"crossref","first-page":"ofv163","DOI":"10.1093\/ofid\/ofv163","article-title":"Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008\u20132014","volume":"2","author":"Vallabhaneni","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2024092714523924400_ofae525-B28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13054-018-2231-6","article-title":"Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies?","volume":"22","author":"Honore","year":"2018","journal-title":"Crit Care"},{"key":"2024092714523924400_ofae525-B29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5935\/0103-507X.20200044","article-title":"Pharmacokinetics of micafungin in patients treated with extracorporeal membrane oxygenation: an observational prospective study","volume":"32","author":"L\u00f3pez-S\u00e1nchez","year":"2020","journal-title":"Rev Bras Ter Intensiva"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae525\/59080766\/ofae525.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/9\/ofae525\/59361610\/ofae525.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/9\/ofae525\/59361610\/ofae525.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T14:52:52Z","timestamp":1727448772000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae525\/7754907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae525","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,8,30]]},"article-number":"ofae525"}}